logo-loader
Health
Nuformix Plc

Nuformix PLC has 'validated its platform' as it works on 'immediate commercial opportunities'

Dan Gooding, chief executive of Nuformix (LON:NFX), caught up with Proactive London's Andrew Scott  soon after raising £1.25mln to help advance its pipeline of drugs.

Gooding says the fundraise strengthens its position as negotiations continue in Asia for its NXP2 asset.

Quick facts: Nuformix Plc

Price: 7.2 GBX

Market: LSE
Market Cap: £33.82 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular...

Proactive Research analyst Emma Ulker gives her view on the work MaxCyte Inc's (LON:MXCT) doing in the area of cell and gene therapy. MXCT has more than 80 licensed programmes including more than 45 licensed for clinical use. They've announced seven clinical/commercial partnership deals...

3 days, 15 hours ago

2 min read